Journal article
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease
Victor L Villemagne, Shozo Furumoto, Michelle T Fodero-Tavoletti, Rachel S Mulligan, John Hodges, Ryuichi Harada, Paul Yates, Olivier Piguet, Svetlana Pejoska, Vincent Dore, Kazuhiko Yanai, Colin L Masters, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | SPRINGER | Published : 2014
Abstract
PURPOSE: Diagnosis of tauopathies such as Alzheimer's disease (AD) still relies on post-mortem examination of the human brain. A non-invasive method of determining brain tau burden in vivo would allow a better understanding of the pathophysiology of tauopathies. The purpose of the study was to evaluate (18)F-THK523 as a potential tau imaging tracer. METHODS: Ten healthy elderly controls, three semantic dementia (SD) and ten AD patients underwent neuropsychological examination, MRI as well as (18)F-THK523 and (11)C-Pittsburgh compound B (PIB) positron emission tomography (PET) scans. Composite memory and non-memory scores, global and hippocampal brain volume, and partial volume-corrected tiss..
View full abstractRelated Projects (9)
Grants
Awarded by Alzheimer Drug Discovery Foundation Research Grant
Awarded by National Health and Medical Research Council of Australia Project
Awarded by Grants-in-Aid for Scientific Research
Funding Acknowledgements
We thank Prof. Michael Woodward, Dr. John Merory, Dr. Gordon Chan, Dr. Kenneth Young, Dr. David Darby, Ms. Fiona Lamb and the Brain Research Institute for their assistance with this study. The study was partially supported by an Alzheimer Drug Discovery Foundation Research Grant (20101208 AFTD) and by a National Health and Medical Research Council of Australia Project Grant 1044361. The funding sources had no input into the design and conduct of the study; collection, management, analysis and interpretation of the data; and in the preparation, review, approval or decision to submit the manuscript for publication.